ATUM

ATUM positions itself as a collaborative life science partner, combining client expertise with its own to deliver integrated solutions across gene design and synthesis, antibody services, cell line development, and protein expression. Operating under the model that projects succeed through partnership rather than transactional service delivery, the company serves biopharmaceutical researchers and development teams requiring specialist biological engineering support.

The company offers a broad platform spanning gene-level work through to protein analytics and assay development. Its codon optimisation capability and GPS Technology feed into expression testing across bacterial, mammalian, yeast, and other host systems, giving clients flexibility at the lead optimisation stage. Protein engineering and biological engineering round out the technical portfolio.

Among its proprietary platforms, Lock-In accelerates the identification of bispecific antibody candidates suitable for cell line development, while lightningHEK enables massively parallel lead candidate antibody expression alongside binding and developability studies. The discoCHO platform delivers transient expression in CHO-K1 cells, addressing speed requirements during lead optimisation. These platforms are supported by catalogued expression vectors for bacterial, mammalian, and yeast systems, as well as CRISPR/Cas9 vectors and a range of reagents including Electra and ProteinPaintbox.

Researchers also have access to digital tools including Gene Designer, DNA Atlas, and a gRNA Designer, supporting in silico work upstream of wet laboratory activities. The combination of proprietary platforms, catalogue products, and software tooling positions ATUM as a vertically integrated resource for biologic development programmes.

Further information is available at atum.bio.